Holen Sie sich die Stockscreener-App
5.54
0.73%
0.04
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Aligos Therapeutics Inc (ALGS-Q) Stock Price and News - The Globe and Mail
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement - TipRanks
ALGS Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.15%EPS Miss Report - dars.gov.et
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Technical Reactions to ALGS Trends in Macro Strategies - Stock Traders Daily
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus By Investing.com - Investing.com India
Liquidity Mapping Around (ALGS) Price Events - Stock Traders Daily
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Investing News Network
Why is Aligos Therapeutics stock rallying 7% today? - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com India
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Yahoo Finance
Stock Market News - Investing.com South Africa
Aligos Therapeutics (ALGS) Stock Forum and Discussion - Moomoo
Aligos Therapeutics and Katholieke Universiteit Leuven patent new Mpro inhibitors - BioWorld News
ALGS Q2 2026 Earnings: EPS Beats Estimates by 87% but Shares Slide 14.5%Earnings Outlook Update - dars.gov.et
Aligos Therapeutics Inc (ALGS) Peer Comparison – Compare with Others - Value Research
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - The Manila Times
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Share Repurchase Impact - dars.gov.et
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):